Thank you, Madam Chair. In response to the Member’s question, I think the privacy of the information here will be very, very sensitive and the information will be very sensitive and the privacy is paramount to that information.
We will need to create many checks and balances about who has access to that information and when and even if that is available on what we call a non- nominal basis. So when it’s first looked at as screening data. you do not even know the name of the person that’s attached to it. The finer details of this we will definitely have to work out as we go to how the prescription monitoring program will work, but privacy of patients is certainly paramount to the success of this.